Is It Time to Change the Standard of Care for Fit Patients With AML? David Brzostowicki

https://www.medscape.com/viewarticle/it-time-change-standard-care-fit-patients-aml-2026a10015lk For decades, the first treatment for a fit adult with acute myeloid leukemia (AML) has been intensive induction chemotherapy: typically, 7 days of cytarabine plus 3 days of an anthracycline. The regimen works often enough to remain the standard, but it puts patients in the hospital for nearly a month, drives blood counts low enough to cause serious infections and bleeding, and cures a minority of those with high-risk disease.